Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28255318 | 0.84 | — | — | |
| SCHEMBL16212615 | 0.72 | MGLL (0.36) | — | |
| SCHEMBL21195136 | 0.72 | MGLL (0.36) | — | |
| SCHEMBL14255598 | 0.71 | — | — | |
| SCHEMBL6780768 | 0.69 | — | — | |
| SCHEMBL6780773 | 0.69 | — | — | |
| SCHEMBL8106145 | 0.68 | CYP1A2 (0.42) | LMNATSHR | |
| SCHEMBL7337061 | 0.67 | CYP1A2 (0.38) | LMNATSHR | |
| Hydrochloric Acid SCHEMBL19667902 | 0.66 | MEN1 (0.33) | — | |
| Hydrochloric Acid SCHEMBL15476103 | 0.66 | MEN1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120258967-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| US-20100041674-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258967-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | PIK3CA, PIK3CB, PIK3C2B | LMNA 3776/4885TSHR 4020/4885NOS1 3975/4885 |
| US-20100041674-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | LMNA 3795/4885TSHR 4633/4885NOS1 3304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.